|
1.
|
|
9 p, 1.1 MB |
The biological basis of disease recurrence in psoriasis : a historical perspective and current models
/
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Costanzo, Antonio (Humanitas University) ;
Muñoz-Elías, Ernesto J. (Janssen Research & Development) ;
Jazra, Maria (Medical Affairs) ;
Wegner, Sven (Janssen-Cilag GmbH) ;
Paul, Carle (Hôpital Larrey) ;
Conrad, Curdin (University Hospital CHUV) ;
Universitat Autònoma de Barcelona
A key challenge in psoriasis therapy is the tendency for lesions to recur in previously affected anatomical locations after treatment discontinuation following lesion resolution. Available evidence supports the concept of a localized immunological 'memory' that persists in resolved skin after complete disappearance of visible inflammation, as well as the role of a specific subpopulation of T cells characterized by the dermotropic CCR4 phenotype and forming a local memory. [...]
2022 -  10.1111/bjd.20963
British journal of dermatology, Vol. 186 Núm. 5 (may 2022) , p. 773-781
|
|
|
2.
|
|
14 p, 695.4 KB |
Comparative effectiveness of biologics in clinical practice : week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO)
/
Pinter, Andreas (University Hospital of Frankfurt (Alemanya)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Schäkel, Knut (Heidelberg University Hospital (Alemanya)) ;
Reich, Adam (Institute of Medical Sciences. Medical College of Rzeszow University) ;
Zaheri, Shirin (Imperial College Healthcare NHS Trust) ;
Costanzo, Antonio (Humanitas Research Hospital Pieve Emanuele (Milà, Itàlia)) ;
Tsai, Tsen-Fang (National Taiwan University Hospital and National Taiwan University College of Medicine) ;
Smith, Saxon Donald (Australian National University,College of Health and Medicine) ;
Lynde, Charles W. (University of Toronto) ;
Brnabic, Alan (Eli Lilly and Company) ;
Reed, Catherine L. (Eli Lilly and Company) ;
Hill, Julie (Eli Lilly and Company) ;
Schuster, Christopher F. (Medical University of Vienna) ;
Riedl, Elisabeth (Medical University of Vienna) ;
Paul, Carle (Paul Sabatier University and Larrey Hospital (Toulose, França)) ;
Universitat Autònoma de Barcelona
Background: Clinical trials study treatment outcomes under stringent conditions, capturing incompletely the heterogeneity of patient populations and treatment complexities encountered in real-world practice. [...]
2022 - 10.1111/jdv.18376
Journal of the European Academy of Dermatology and Venereology, Vol. 36 Núm. 11 (november 2022) , p. 2087-2100
|
|
|
3.
|
|
1 p, 118.3 KB |
Correction to : Evolution of Patient Perceptions of Psoriatic Disease: Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey
/
Lebwohl, Mark (Icahn School of Medicine at Mount Sinai) ;
Langley, Richard G. (Dalhousie University) ;
Paul, Carle (Paul Sabatier University) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Reich, Kristian (University Medical Center Hamburg-Eppendorfi) ;
van de Kerkhof, Peter (Radboud University Medical Center) ;
Wu, Hsiuan-Lin (Amgen Inc) ;
Richter, Sven (Amgen Inc) ;
Jardon, Shauna (Amgen Inc) ;
Gisondi, Paolo (University Hospital of Verona (Itàlia)) ;
Universitat Autònoma de Barcelona
2022 - 10.1007/s13555-021-00656-z
Dermatology and Therapy, Vol. 12 (january 2022) , p. 79
|
|
|
4.
|
|
16 p, 894.7 KB |
Evolution of Patient Perceptions of Psoriatic Disease : Results from the Understanding Psoriatic Disease Leveraging Insights for Treatment (UPLIFT) Survey
/
Lebwohl, Mark (Icahn School of Medicine at Mount Sinai) ;
Langley, Richard G. (Dalhousie University) ;
Paul, Carle (Paul Sabatier University) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Reich, Kristian (University Medical Center Hamburg-Eppendorf) ;
van de Kerkhof, Peter (Radboud University Medical Center) ;
Wu, Hsiuan-Lin (Amgen Inc) ;
Richter, Sven (Amgen Inc) ;
Jardon, Shauna (Amgen Inc) ;
Gisondi, Paolo (University Hospital of Verona (Itàlia)) ;
Universitat Autònoma de Barcelona
Since the 2012 Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) survey, several systemic treatments for psoriasis (PsO) and/or psoriatic arthritis (PsA) have been approved. The population-based UPLIFT survey was conducted to understand how perceptions of treatment-related outcomes have evolved, particularly for patients with mild to moderate PsO and/or PsA and their dermatologists. [...]
2021 - 10.1007/s13555-021-00635-4
Dermatology and Therapy, october 2021, p. 1-16
|
|
|
5.
|
|
18 p, 504.6 KB |
Safety of Ixekizumab Treatment for up to 5 Years in Adult Patients with Moderate-to-Severe Psoriasis : Results from Greater Than 17,000 Patient-Years of Exposure
/
Armstrong, April W (Keck School of Medicine of the University of Southern California. Department of Clinical Research) ;
Paul, Carle (Paul Sabatier University. Dermatology Department, Toulouse University Hospital (CHU)) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Boehncke, Wolf-Henning (University of Geneva. Department of Pathology and Immunology) ;
Freeman, Michael (The Skin Centre, Benowa, QLD Australia) ;
Torii, Hideshi (Tokyo Yamate Medical Center. Division of Dermatology) ;
Papp, Kim (K Papp Clinical Research and Probity Medical Research) ;
Griffiths, Christopher E. M. (NIHR Manchester Biomedical Research Centre. Dermatology Centre, Salford Royal Hospital, University of Manchester) ;
Blauvelt, Andrew (Oregon Medical Research Center) ;
Reich, Kristian (Skinflammation® Center, Hamburg, Germany) ;
Gooderham, Melinda (Centre for Dermatology and Probity Medical Research, Peterborough, ON Canada) ;
Terui, Tadashi (Nihon University School of Medicine. Department of Dermatology) ;
Renda, Lisa (Eli Lilly and Company) ;
Agada, Noah (Eli Lilly and Company) ;
Xu, Wen (Eli Lilly and Company) ;
Gallo, Gaia (Eli Lilly and Company) ;
Lebwohl, Mark G. (Icahn School of Medicine at Mount Sinai. Department of Dermatology) ;
Universitat Autònoma de Barcelona
Long-term safety data are critical for evaluating therapies for psoriasis. Ixekizumab has demonstrated efficacy and is well tolerated for the treatment of moderate-to-severe plaque psoriasis. We examined the safety and tolerability of up to 5 years of ixekizumab therapy in patients with psoriasis. [...]
2019 - 10.1007/s13555-019-00340-3
Dermatology and Therapy, Vol. 10 (november 2019) , p. 133-150
|
|
|
6.
|
|
10 p, 285.5 KB |
Pimecrolimus in atopic dermatitis : Consensus on safety and the need to allow use in infants
/
Luger, Thomas (University of Münster. Department of Dermatology) ;
Boguniewicz, Mark (Division of Pediatric Allergy-Immunology, Department of Pediatrics, National Jewish Health and University of Colorado School of Medicine) ;
Carr, Warner (Southern California Research) ;
Cork, Michael (Academic Unit of Dermatology Research, Department of Infection and Immunity, The University of Sheffield, K Floor, The Medical School (RHH Tower)) ;
Deleuran, Mette (Aarhus University Hospital (Aarhus, Dinamarca)) ;
Eichenfield, Lawrence (Departments of Pediatrics and Medicine, University of California, San Diego School of Medicine, Rady Children's Hospital) ;
Eigenmann, Philippe (Pediatric Allergy Unit, Children's University Hospital) ;
Fölster-Holst, Regina (Department of Dermatology, University Clinics of Schleswig-Holstein) ;
Gelmetti, Carlo (Department of Pathophysiology and Transplantation, University of Milan, Clinica Dermatologica, Fondazione I.R.C.C.S. Ca' Granda "Ospedale Maggiore Policlinico") ;
Gollnick, Harald (Department of Dermatology & Venereology, Otto-von-Guericke University of Magdeburg) ;
Hamelmann, Eckard (Allergy Center Ruhr, Ruhr-University Bochum, & Evangelisches Krankenhaus Bielefeld, Klinik für Kinder und Jugendmedizin) ;
Hebert, Adelaide A. (Departments of Dermatology and Pediatrics, The University of Texas Medical School-Houston) ;
Muraro, Antonella (Food Allergy Referral Centre, Department of Woman and Child Health, University Hospital of Padua) ;
Oranje, Arnold P. (Intermedica Dermatology and Hair Clinic) ;
Paller, Amy S. (Departments of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine) ;
Paul, Carle (Dermatology Department, INSERM 1056, Paul Sabatier University, Larrey Hospital) ;
Puig Sanz, Lluís (Institut d'Investigació Biomèdica Sant Pau) ;
Ring, Johannes (Technische Universität München) ;
Siegfried, Elaine (Departments of Pediatrics and Dermatology, Saint Louis University School of Medicine) ;
Spergel, Jonathan M. (Children's Hospital of Philadelphia (Pennsilvània)) ;
Stingl, Georg (Department of Dermatology, Medical University of Vienna) ;
Taieb, Alain (Service de Dermatologie et Dermatologie Pédiatrique Centre de référence pour les maladies rares de la peau, INSERM 1035, Université de Bordeaux) ;
Torrelo, Antonio (Hospital Infantil Universitario Niño Jesús (Madrid)) ;
Werfel, Thomas (Department of Dermatology and Allergy, Hannover Medical School) ;
Wahn, Ulrich (Department of Pediatric Pneumology and Immunology, Charite) ;
Universitat Autònoma de Barcelona
Atopic dermatitis (AD) is a distressing dermatological disease, which is highly prevalent during infancy, can persist into later life and requires long-term management with anti-inflammatory compounds. [...]
2015 - 10.1111/pai.12331
Pediatric Allergy and Immunology, Vol. 26 (april 2015) , p. 306-315
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
